Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701364 | 0.86 | SLC16A3 (0.43) | KDM4EALDH1A1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL701110 | 0.85 | KDM4E (0.40) | NR4A2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL1079605 | 0.83 | PTGER4 (0.43) | PTGER4CSF1R | |
| SCHEMBL701351 | 0.82 | NR4A2 (0.42) | NR4A2KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL701653 | 0.82 | PIK3CB (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL27832050 | 0.81 | NR4A2 (0.40) | NR4A2KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL699989 | 0.73 | HTR3A (0.42) | — | |
| SCHEMBL699988 | 0.73 | HTR3A (0.42) | — | |
| SCHEMBL700433 | 0.72 | HTR3A (0.41) | — | |
| SCHEMBL700434 | 0.72 | HTR3A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710047-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| CN-102046176-B | 5-HT3Receptor modulators, methods of preparation and uses thereof | ALBANY MOLECULAR RES INC | 2013-08-07 | — | — | CN | disclosed |
| US-8501729-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8124600-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| CN-102046176-A | 5-HT3Receptor modulators, methods of preparation and uses thereof | ALBANY MOLECULAR RES INC | 2011-05-04 | — | — | CN | disclosed |
| EP-2310019-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009155054-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | NR4A2 3653/4885KDM4E 3629/4885ALDH1A1 2992/4885 |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | NR4A2 3653/4885KDM4E 3629/4885ALDH1A1 2992/4885 |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | NR4A2 3653/4885KDM4E 3629/4885ALDH1A1 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.